Abstract
We employed second-generation photosensitizer, Talaporfin sodium, for the intra-operative
photodynamic diagnosis (PDD) and photodynamic therapy (PDT) for glioblastoma patients. 22
consecutive patients with glioblastoma (16 newly diagnosed and 6 recurrence) received intravenous
dosed of Talaporfin sodium (40 mg/m2) 24 hours prior to craniotomy. Intra-operatively, tumor
fluorescence was visualized using modified diode laser (664 nm) mounted surgical microscope.
Fluorescence-guided resection of tumor tissue was performed, and additional PDT (150 mW/cm2,
27 J/cm2) was performed to 11 cases on invading tissues in eloquent area. A clear fluorescence signal
was demonstrated in the tumor bulk and peritumoral zone, and the satisfactory resection of contrastenhancing
tumor was confirmed and achieved 9 months of median survival time. Mild liver dysfunction
was occurred in 11.6% of cases, and skin photosensitivity was occurred in 1 case. The clinical
experience in this study indicates the clinical feasibility of Talaporfin-induced PDD and PDT for
glioblastoma patients.
